

ATN-161

Catalog No: tcsc3327



Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg

Size: 100mg



Specifications

CAS No:

262438-43-7

Formula:

$C_{23}H_{35}N_9O_8S$

Pathway:

Cytoskeleton

Target:

Integrin

Purity / Grade:

>98%

Solubility:

10 mM in DMSO

Observed Molecular Weight:

597.64

Product Description


ATN-161 is a novel **integrin $\alpha 5\beta 1$**

antagonist, which inhibits angiogenesis and growth of liver metastases in a murine model.

IC50 & Target: Integrin $\alpha 5\beta 1$ ^[1]

In Vitro: The combination of ATN-161 plus 5-FU significantly reduces tumor cell proliferation compared to control and single-agent therapy (p[1]. ATN-161 inhibits VEGF-induced migration and capillary tube formation in hCECs, but did not inhibit proliferation. ATN-161 decreases the number of cells migrating in response to VEGF in a dose-dependent manner starting at 100 nM (P[2].

In Vivo: The preliminary experiments with $\alpha 5\beta 1$ -negative human colon cancer xenografts (HT29) show that treatment with ATN-161 significantly reduces tumor weight and vessel density^[1]. Injection of ATN-161 after laser photocoagulation inhibits choroidal neovascularization (CNV) leakage and neovascularization to an extent similar to AF564^[2].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!